How do Eylea and Lucentis compare in clinical trials?
Eylea (aflibercept) and Lucentis (ranibizumab) both treat wet age-related macular degeneration (AMD) by blocking VEGF to reduce vision loss. Head-to-head trials show Eylea often requires fewer injections for similar or better visual outcomes. The VIEW1 and VIEW2 phase 3 trials (2010) compared Eylea 2 mg every 8 weeks (after three monthly doses) to monthly Lucentis 0.5 mg. Eylea matched Lucentis in mean vision improvement (+8 to +10 letters on ETDRS chart at 52 weeks) but with 33-37% fewer injections.[1][2]
Does Eylea work better for specific conditions like DME or RVO?
For diabetic macular edema (DME), Eylea outperforms Lucentis in some metrics. VISTA and VIVID trials found Eylea 2 mg every 8 weeks improved vision by +12.5 letters versus +10.5 for Lucentis every 4 weeks at year 1, again with fewer injections.[3] In retinal vein occlusion (RVO), COPERNICUS and GALILEO trials showed Eylea gaining +16.9 to +18.3 letters versus +13.9 to +14.9 for standard care (often Lucentis-like regimens).[4] Real-world data from 2020 studies confirm Eylea patients often gain more vision letters over 2-5 years.[5]
Why might Eylea seem more effective overall?
Eylea's higher binding affinity to VEGF-A and placental growth factor allows longer dosing intervals (every 8-12 weeks after loading) compared to Lucentis's monthly schedule, improving adherence and anatomic outcomes like retinal thickness reduction.[6] Meta-analyses (e.g., 2019 Cochrane review) find no significant vision difference at 1 year but Eylea superior at 2 years for AMD (+1.3 letters) and DME (+2.9 letters).[7]
What do patients and doctors report in practice?
Retrospective studies like IRIS Registry data (2015-2020) show Eylea users with slightly better 2-year vision gains in wet AMD (7.2 vs 6.8 letters for Lucentis), though confounding factors like patient selection exist.[8] Ophthalmologists often prefer Eylea for its convenience, but efficacy is comparable—choice depends on cost, insurance, and injection burden.
Are there cases where Lucentis performs better?
Lucentis has a longer safety track record and lower risk of anti-VEGF resistance in some myopic choroidal neovascularization cases. No major trials show it superior head-to-head, but it's approved for more pediatric indications.[9]
[1]: Regeneron. VIEW1/VIEW2 trial results. NEJM 2012. https://www.nejm.org/doi/full/10.1056/NEJMoa1102673
[2]: FDA label, Eylea. https://www.accessdata.fda.gov/drugsatfdadocs/label/2011/125387lbl.pdf
[3]: VISTA/VIVID trials. Ophthalmology 2015. https://www.aaojournal.org/article/S0161-6420(14)00769-9/fulltext
[4]: COPERNICUS/GALILEO. Ophthalmology 2015. https://www.aaojournal.org/article/S0161-6420(14)01058-1/fulltext
[5]: Real-world evidence review. Retina 2020. https://journals.lww.com/retinajournal/fulltext/2020/05000/realworldoutcomesofafliberceptvsranibizumab.12.aspx
[6]: Drug mechanisms. Nature Reviews Drug Discovery 2012.
[7]: Cochrane Database Syst Rev 2019. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012019.pub2/full
[8]: IRIS Registry study. JAMA Ophthalmol 2021. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2784012
[9]: FDA labels comparison. Lucentis: https://www.accessdata.fda.gov/drugsatfdadocs/label/2006/125409lbl.pdf